［1］Siegel R，Naishadham D，Jemal A.Cancer statistics，2012［J］.CA Cancer J Clin，2012，62(1)：10-29.
[2]Ladenstein R，Potschger U，Le Deley MC，et al.Primary disseminated multifocal Ewing sarcoma：Results of the Euro-EWING 99 trial［J］.J Clin Oncol，2010，28(20)：3284-3291.
[3]Lorigan P，Verweij J，Papai Z，et al.Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma：A European organisation for research and treatment of cancer soft tissue and bone sarcoma group study［J］.J Clin Oncol，2007，25：3144-3150.
[4]Hensley ML，Blessing JA，Mannel R，et al.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma：A Gynecologic Oncology Group phase II trial［J］.Gynecol Oncol，2008，109(3)：329-334.
[5]Dileo P，Morgan JA，Zahrieh D，et al.Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas：Results of a phase II trial［J］.Cancer，2007，109：1863-1869.
[6]Maki RG，Wathen JK，Patel SR，et al.Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas：Results of sarcoma alliance for research through collaboration study 002 ［corrected］［J］.Clin Oncol，2007，25：2755-2763.
[7]Schmitt T，Kosely F，Wuchter P，et al.Gemcitabine and docetaxel for metastatic soft tissue sarcoma-a single center experience［J］.Onkologie，2013，36：415-420.
[8]Kaya AO，Büyükberber S，Ozkan M，et al.Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma［J］.Asian Pac J Cancer Prev，2012，13：463-467.
[9]Clark MA，Fisher C，Judson I，et al.Soft-tissue sarcomas in adults［J］.N Engl J Med，2005，353(7)：701-711.
[10]Samia Arifi，Rhizlan Belbaraka，Rabie Rahhali，et al.Treatment of adult soft tissue sarcomas：An overview［J］.Rare Cancers Ther，2015，3：69-87.
[11]Hensley ML，Blessing JA，Degeest K，et al.Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma：A Gynecologic Oncology Group phase Ⅱ study［J］.Gynecol Oncol，2008，109(3)：323-328.
[12]Hensley ML，Blessing JA，Mannel R，et al.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma：A Gynecologic Oncology Group phase Ⅱ trial［J］.Gynecol Oncol，2008，109(3)：329-334.
[13]Pautier P，Floquet A，Penel N，et al.Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas：A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)［J］.Oncologist，2012，17(9)：1213-1220.
[14]Folkman J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action［J］.Exp Cell Res，2006，312：594-607.
[15]Ling Y，Yang Y，Lu N，et al.Endostar，a novel recombinant human endostatin，exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells［J］.Biochem Biophys Res Commun，2007，361：79-84.
[16]Zhang LP，Liao XY，Xu YM，et al.Efficacy and safety of endostar (R) combined with chemotherapy in patients with advanced soft tissue sarcomas［J］.Asian Pac J Cancer Prev，2013，14：4255-4259.
[17]Xu M，Xu CX，Bi WZ，et al.Effects of endostar combined multidrug chemotherapy in osteosarcoma［J］.Bone，2013，57：111-115.
[18]Hensley ML，Miller A，O' Malley DM，et al.Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma：An NRG Oncology/Gynecologic Oncology Group study［J］.J Clin Oncol，2015，33(10)：1180-1185.